Skip to content

Nuvation Bio NUVB Contract With Customer Liabilities Current

Contract With Customer Liabilities Current at other companies

Marriott Vacations Worldwide logo
Marriott Vacations WorldwideVAC
$466M
Target Hospitality logo
Target HospitalityTH
$12.71M+3,987%
OSI Systems logo
OSI SystemsOSIS
$60M-4.7%
HTF
Heartflow, Inc. Common StockHTFL
$148K+112%
State Street logo
State StreetSTT
$141M+3.7%
UFP Technologies logo
UFP TechnologiesUFPT
$1.48M-26.5%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:ContractWithCustomerLiabilitiesCurrent.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's contract with customer liabilities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's contract with customer liabilities current?
Nuvation Bio (NUVB) reported contract with customer liabilities current of $9.74M in Q1 2026.
What does contract with customer liabilities current mean?
This represents deferred revenue or obligations arising from contracts with customers where the company has received payment but has not yet satisfied the underlying performance obligations. It serves as a leading indicator of future revenue recognition once the specific milestones or services are delivered. For clinical-stage companies, this may reflect upfront payments from collaboration or licensing agreements.